Core Insights - Zhifei Biological's subsidiary, Beijing Zhifei Lvzhu, has successfully obtained invention patent certificates from the U.S. Patent and Trademark Office and the European Patent Office for a combined vaccine targeting respiratory syncytial virus (RSV) infection, showcasing the company's strong independent research and development capabilities and marking a significant recognition of its technological innovation in global core markets [1][3] Group 1: Patent and Innovation - The RSV combined vaccine patent is a significant achievement resulting from deep collaboration between Zhifei Lvzhu and Beijing Jiaotong University, addressing the urgent clinical need for effective preventive measures against RSV, a major pathogen causing lower respiratory infections in infants and the elderly [3] - The patented technology enhances immune response efficiency and broad-spectrum protection through innovative antigen design and delivery strategies, providing safer and more effective preventive measures for high-risk populations [3] - Zhifei Biological has strengthened its intellectual property system, achieving over 60 domestic and international invention patent authorizations, with this patent previously authorized in China and Russia, supporting its globalization strategy and enhancing its core competitiveness in the respiratory disease vaccine sector [3][4] Group 2: International Expansion - The company is accelerating its product internationalization process and enhancing international collaboration, contributing positively to global infectious disease control and exploring new market opportunities [4] - Zhifei's self-developed products have been exported to over 10 countries, with clinical trials or registration efforts underway in nearly 20 countries, including successful market registration of tuberculosis diagnostic reagents in Indonesia and ongoing supply of quadrivalent meningococcal polysaccharide vaccine in several countries [4] - The company is expanding its international layout from preventive to therapeutic areas, with discussions ongoing for therapeutic products like insulin and semaglutide with multiple overseas entities [4][6] Group 3: Future Directions - Zhifei Biological plans to continue its commitment to innovative research and development, strengthen its global intellectual property protection network, and solidify its vaccine research and development technology, aiming to create a competitive product matrix and contribute more Chinese wisdom and solutions to global public health [6]

Group 1 - The core point of the article is that Zhifei Biological (SZ 300122) announced the acquisition of a patent for a combined vaccine targeting respiratory syncytial virus (RSV) infection, which could enhance its product portfolio and market position [1] - Zhifei Biological's revenue composition for the year 2024 is projected to be 99.14% from biological products and 0.86% from other businesses, indicating a strong focus on its core offerings [1] - As of the report, Zhifei Biological has a market capitalization of 48.7 billion yuan, reflecting its significant presence in the biotechnology sector [1]